Addus HomeCare (ADUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH). But which of these two stocks offers value investors a better bang for their buck right now?
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. HALO, LDOS, ATO & ADUS are sound enough to meet financial obligations.
Although the revenue and EPS for Addus HomeCare (ADUS) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Addus HomeCare (ADUS) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.20 per share. This compares to earnings of $1.07 per share a year ago.
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Addus HomeCare (ADUS) and Chemed (CHE). But which of these two companies is the best option for those looking for undervalued stocks?
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Addus HomeCare (ADUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On Wall Street, small-cap stocks often present unique opportunities for significant growth. These under-the-radar companies are typically not as well-known or widely covered by analysts as their large-cap counterparts.